Omeprazole Ibigen

Omeprazole, the active ingredient in Omeprazole Ibigen, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces gastric acid secretion and is used to manage conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Omeprazole Ibigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole Ibigen is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions: - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: accelerates healing of erosive lesions in the oesophagus. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumours. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.

Omeprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild, transient headache reported by some patients. - Diarrhoea: loose stools occurring during early treatment. - Abdominal pain: mild discomfort or cramping. - Nausea: occasional feeling of queasiness. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis associated with altered gut flora. - Osteoporosis‑related fractures: increased risk of hip, wrist or vertebral fractures with long‑term use. - Acute interstitial nephritis: sudden kidney inflammation presenting with reduced urine output. - Severe cutaneous adverse reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypomagnesemia: low serum magnesium levels, especially with prolonged therapy. - Vitamin B12 deficiency: reduced absorption leading to anemia over extended periods.

When using Omeprazole Ibigen, consider the following safety measures: - Assess renal function: adjust use in patients with severe kidney impairment. - Evaluate bone health: monitor long‑term users for signs of decreased bone density. - Review concomitant medications: consider potential interactions that may alter drug levels. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Discontinue before surgery: stop use prior to procedures requiring gastric acidity. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole Ibigen can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atorvastatin: increased plasma concentrations, raising the potential for muscle toxicity. - Methotrexate: elevated levels may enhance toxicity, especially in high‑dose regimens.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent coagulation monitoring. - Digoxin: modest rise in serum digoxin, warranting periodic level checks. - Phenytoin: altered metabolism may change seizure‑control efficacy.